All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy


Now you can personalise
your MPN Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more

The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
You're logged in! Click here any time to manage your account or log out.
You're logged in! Click here any time to manage your account or log out.

Impact of allo-HSCT on survival outcomes in accelerated/blast-phase MPN

Jul 9, 2024
Learning objective: After reading this article, learners will be able to cite a new clinical development in blast-phase MPN.

A multicenter analysis that evaluated the survival outcomes associated with first-line treatment, response, and allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with accelerated/blast-phase myeloproliferative neoplasms (MPN-AP/BP) has been published in Blood Advances by Patel et al.1  

Key learnings1

Across 9 academic centers, the three most common first-line treatments for adult patients with MPN-AP/BP were intensive chemotherapy (IC), DNA methyltransferase inhibitor (DNMTi)-based regimens, and DNMTi combined with venetoclax (VEN). 

The median overall survival (OS) for patients with MPN-AP/BP was 0.86 years, regardless of first-line treatment. 

The median OS for patients who underwent allo-HSCT was 2.3 years from the time of transplant. 

These data highlight an unmet need in treating MPN-AP/BP, suggesting that current therapies provide limited survival benefits in the absence of allo-HSCT.  

There is a need for further research and development of more effective treatments for patients who are ineligible for or unable to receive allo-HSCT. 

  1. Patel A, Yoon J, Johnston H, et al. Treatment approach and outcomes of patients with accelerated/blast-phase myeloproliferative neoplasms in the current era. Blood Adv. 2024. Online ahead of print. DOI: 10.1182/bloodadvances.2024012880 


Subscribe to get the best content related to MPN delivered to your inbox